Skip to main content

Academy of Scholars research symposium prompts dialogue about latest in science

Annette T. Lee, PhD, (left) with Louis W. Sullivan, MD, and Kevin. J. Tracey, MD
Annette T. Lee, PhD, (left) with Louis W. Sullivan, MD, and Kevin. J. Tracey, MD

Leading scientists in health equity, outcomes, cancer treatment, trauma immunology, sepsis and more share knowledge in hopes to cure disease

HUNTINGTON, NY —

Feinstein Academy of Scholars, an integrated network of researchers and scholars who share a passion to revolutionize translational research, recently hosted its annual symposium. The event featured keynote speeches from a number of leading scientists in the areas of health equity in medicine, health outcomes, cancer treatment, trauma immunology, sepsis and stem cell-based approaches to metabolic disease.

The Academy brings together scientists who share the mission of the Feinstein Institute for Medical Research to produce knowledge to cure disease. Members of the Academy include recipients of an honorary doctoral degree from the Elmezzi Graduate School of Molecular Medicine, Marsh and Match visiting lecturers and recipients of its Cerami, Ross or Advancing Women in Science and Medicine (AWSM) prizes.

“The annual Feinstein Academy convenes leading scientists previously honored by the Feinstein Institute with Match and Marsh Lectures, Cerami and Ross Prizes, and with Elmezzi Graduate School alumni making significant contributions to science and medicine,” said Kevin. J. Tracey, MD, president and CEO of the Feinstein Institute. “It is an international scientific event fostering new seeds of innovation and collaboration.”

This year, the symposium’s attendees – who gathered at Oheka Castle in Huntington, N.Y. on May 22 – heard lectures from:

  • Louis W. Sullivan, MD, of The Morehouse School of Medicine, who highlighted the issue of health equity across the country and the need to move the needle forward;
  • Thomas McGinn, MD, director of the Feinstein Institute’s Institute of Health Innovations & Outcomes Research, who focused his remarks on the importance of developing evidence-based interventions to improve health outcomes;
  • Levi A. Garraway, MD, PhD, of Eli Lilly and Company, who discussed the latest developments to bring precision medicine to cancer patients;
  • Timothy R. Billiar, MD, of the University of Pittsburgh, who reviewed the topic of the immune system’s response after injury;
  • Ben Lu, MD, PhD, a 2013 graduate of The Elmezzi Graduate School where he was mentored by Dr. Tracey, and currently serving at the China-based Third Xiangya Hospital of Central South University, who detailed his latest work on immunothrombosis in sepsis;
  • and Rudolph L. Leibel, MD, of Columbia University, who presented his latest research on the use of stem cell-based approaches to analyze the physiology of diabetes and obesity.

“The event offers a unique interdisciplinary forum for our investigators, physicians and staff to connect and share their latest in translational research with the goal of producing knowledge to cure disease,” said Annette T. Lee, PhD, dean of the Elmezzi Graduate School of Molecular Medicine and associate professor at the Feinstein Institute.